Literature DB >> 9703430

Exclusion of a p53 germline mutation in a classic Li-Fraumeni syndrome family.

S C Evans1, B Mims, K M McMasters, C J Foster, M deAndrade, C I Amos, L C Strong, G Lozano.   

Abstract

Li-Fraumeni syndrome (LFS) is characterized by a high risk of sarcomas, early onset of breast cancer, and a diversity of other cancers occurring as multiple primary tumors in multiple family members. In many families with LFS, germline mutations within the tumor-suppressor gene p53 have been identified. However, mutations in p53 have not been detected in approximately 30% of LFS families. To address the possibility either that p53 mutations were being missed or that another predisposing gene is altered in LFS, we used a variety of methods to accurately determine the p53 status in a large LFS kindred. A transcriptional activation assay on exons 4-10 of p53 excluded a mutation within the DNA-binding domain of p53. Single-stranded conformational-polymorphism analysis, using intronic primers and sequencing of all the coding exons and intron/exon junctions, also yielded no mutations. Finally, linkage analysis excluded potential mutations in the noncoding regions of p53. Our findings exclude the presence of a p53 germline mutation in a classic LFS family.

Entities:  

Mesh:

Year:  1998        PMID: 9703430     DOI: 10.1007/s004390050761

Source DB:  PubMed          Journal:  Hum Genet        ISSN: 0340-6717            Impact factor:   4.132


  8 in total

1.  Generation or birth cohort effect on cancer risk in Li-Fraumeni syndrome.

Authors:  Barry W Brown; Tracy J Costello; Shih-Jen Hwang; Louise C Strong
Journal:  Hum Genet       Date:  2005-11-12       Impact factor: 4.132

Review 2.  Syndromes and constitutional chromosomal abnormalities associated with Wilms tumour.

Authors:  R H Scott; C A Stiller; L Walker; N Rahman
Journal:  J Med Genet       Date:  2006-05-11       Impact factor: 6.318

3.  High metastatic potential in mice inheriting a targeted p53 missense mutation.

Authors:  G Liu; T J McDonnell; R Montes de Oca Luna; M Kapoor; B Mims; A K El-Naggar; G Lozano
Journal:  Proc Natl Acad Sci U S A       Date:  2000-04-11       Impact factor: 11.205

4.  Germline p53 mutations in a cohort with childhood sarcoma: sex differences in cancer risk.

Authors:  Shih-Jen Hwang; Guillermina Lozano; Christopher I Amos; Louise C Strong
Journal:  Am J Hum Genet       Date:  2003-02-27       Impact factor: 11.025

5.  High levels of the p53 inhibitor MDM4 in head and neck squamous carcinomas.

Authors:  Yasmine A Valentin-Vega; Juan A Barboza; Gilda P Chau; Adel K El-Naggar; Guillermina Lozano
Journal:  Hum Pathol       Date:  2007-07-24       Impact factor: 3.466

6.  A novel genetic modifier of p53, mop1, results in embryonic lethality.

Authors:  Susan C Evans; Min Liang; Christopher Amos; Xiangjun Gu; Guillermina Lozano
Journal:  Mamm Genome       Date:  2004-06       Impact factor: 2.957

7.  Lung cancer risk in germline p53 mutation carriers: association between an inherited cancer predisposition, cigarette smoking, and cancer risk.

Authors:  Shih-Jen Hwang; Li Shu-Chung Cheng; Guillermina Lozano; Christopher I Amos; Xiangjun Gu; Louise C Strong
Journal:  Hum Genet       Date:  2003-06-11       Impact factor: 4.132

8.  Intronic TP53 Germline Sequence Variants Modify the Risk in German Breast/Ovarian Cancer Families.

Authors:  Xuan Liu; Hans-Peter Sinn; Hans Ulrich Ulmer; Rodney J Scott; Ute Hamann
Journal:  Hered Cancer Clin Pract       Date:  2004-07-15       Impact factor: 2.857

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.